Q2 EPS Estimates for ArriVent BioPharma Cut by HC Wainwright

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Analysts at HC Wainwright cut their Q2 2025 earnings per share estimates for shares of ArriVent BioPharma in a research note issued on Wednesday, May 14th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.78) per share for the quarter, down from their previous estimate of ($0.71). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($4.26) EPS, Q1 2026 earnings at ($0.69) EPS, Q2 2026 earnings at ($0.73) EPS, Q3 2026 earnings at ($0.76) EPS and Q4 2026 earnings at ($0.80) EPS.

ArriVent BioPharma (NASDAQ:AVBP) last announced its earnings results on Monday, May 12th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($1.24).

Several other brokerages have also issued reports on AVBP. Guggenheim began coverage on ArriVent BioPharma in a research report on Monday, March 10th. They issued a “buy” rating and a $45.00 target price for the company. B. Riley assumed coverage on ArriVent BioPharma in a research report on Thursday, March 20th. They set a “buy” rating and a $37.00 price objective for the company. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $39.17.

ArriVent BioPharma Stock Performance

Shares of NASDAQ:AVBP opened at $19.36 on Friday. ArriVent BioPharma has a 52-week low of $15.47 and a 52-week high of $36.37. The firm has a market capitalization of $662.36 million, a P/E ratio of -5.14 and a beta of 1.47. The stock has a 50 day moving average price of $19.25 and a 200-day moving average price of $24.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Infinitum Asset Management LLC purchased a new stake in ArriVent BioPharma during the 4th quarter valued at $43,794,000. Suvretta Capital Management LLC boosted its stake in ArriVent BioPharma by 21.7% during the 4th quarter. Suvretta Capital Management LLC now owns 2,246,000 shares of the company’s stock valued at $59,833,000 after purchasing an additional 400,838 shares during the last quarter. Vanguard Group Inc. boosted its stake in ArriVent BioPharma by 6.1% during the 1st quarter. Vanguard Group Inc. now owns 1,503,358 shares of the company’s stock valued at $27,797,000 after purchasing an additional 86,067 shares during the last quarter. Octagon Capital Advisors LP boosted its stake in ArriVent BioPharma by 4.2% during the 4th quarter. Octagon Capital Advisors LP now owns 2,059,387 shares of the company’s stock valued at $54,862,000 after purchasing an additional 83,000 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in ArriVent BioPharma during the 1st quarter valued at $819,000. Institutional investors own 9.48% of the company’s stock.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.